NASH

Akero’s NASH drug combined with Ozempic cut liver fat in small study
Akero’s NASH drug combined with Ozempic cut liver fat in small study
Stat
Akero Therapeutics
efruxifermin
NASH
Ozempic
Flag link:
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat
BioSpace
Hepion Pharmaceuticals
clinical trials
NASH
rencofilstat
Flag link:
Future of Intercept’s NASH drug in doubt after FDA panel rejection
Future of Intercept’s NASH drug in doubt after FDA panel rejection
BioPharma Dive
Intercept Pharma
FDA
NASH
obeticholic acid
Flag link:
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
BioPharma Dive
FDA
NASH
OCA
obeticholic acid
Intercept Pharma
Flag link:
Promising candidate for NASH submitted to FDA as IND
Promising candidate for NASH submitted to FDA as IND
Clinical Trials Arena
NeuroBo
FDA
clinical trials
NASH
Flag link:
89Bio Enlivened by Nash success
89Bio Enlivened by Nash success
EP Vantage
89Bio
NASH
Akero Therapeutics
pegozafermin
INTERCEPT
Madrigal Pharmaceuticals
Flag link:
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
Endpoints
89Bio
NASH
clinical trials
gozafermin
Akero Therapeutics
Flag link:
FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful
FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful
Endpoints
FDA
Entasis
Intercept Pharma
sulbactam-durlobactam
obeticholic acid
NASH
Flag link:
Spotlight – What is next in Nash
Spotlight – What is next in Nash
EP Vantage
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Novartis backs away from NASH, furthering its research revamp
Novartis backs away from NASH, furthering its research revamp
BioPharma Dive
Novartis
NASH
Pliant Therapeutics
PLN-1474
Flag link:
Janssen Returns Phase I NASH Candidate to Arrowhead
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Flag link:
Nimbus hopes to strike thrice
Nimbus hopes to strike thrice
EP Vantage
Nimbus Therapeutics
NASH
firsocostat
Flag link:
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
Clinical Trials Arena
FDA
Intercept Pharma
OCA
obeticholic acid
NASH
Flag link:
By summer solstice, we'll know the fate of Intercept's NASH drug
By summer solstice, we'll know the fate of Intercept's NASH drug
Endpoints
Intercept Pharmaceuticals
FDA
NASH
obeticholic acid
OCA
Flag link:
Madrigal shares triple on positive NASH study results
Madrigal shares triple on positive NASH study results
BioPharma Dive
Madrigal Pharmaceuticals
clinical trials
NASH
resmetirom
Flag link:
Axcella axes NASH program, 85% of staff in last-ditch focus on long COVID
Axcella axes NASH program, 85% of staff in last-ditch focus on long COVID
Fierce Biotech
Axcella Therapeutics
NASH
layoffs
COVID-19
Long COVID
Flag link:
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
BioSpace
NASH
Intercept Pharma
Novo Nordisk
Madrigal Pharmaceuticals
Inventiva
Galmed Pharmaceuticals
Flag link:
Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out
Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out
Fierce Biotech
Pfizer
R&D
NASH
breast cancer
eczema
Flag link:
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Fierce Pharma
Intercept Pharma
NASH
obeticholic acid
Ocaliva
clinical trials
FDA
Flag link:
With cash dwindling, Axcella shares look at blinded NASH data
With cash dwindling, Axcella shares look at blinded NASH data
Fierce Biotech
Axcella
NASH
clinical trials
AXA1125
Flag link:

Pages